-
公开(公告)号：US10011642B2
公开(公告)日：2018-07-03
申请号：US15004281
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , A61K38/1825 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides methods of treating diabetes, reducing triglyceride levels, and treating obesity by administering to a subject in need there a fusion protein comprising an FGF21 mutant.
-
公开(公告)号：US09708375B2
公开(公告)日：2017-07-18
申请号：US14776917
申请日：2014-03-14
Applicant: AMGEN INC.
Inventor： Ryan B. Case , Benjamin M. Alba , Alice Bakker , Irwin Chen , Amy N. Duguay , Monica Florio , Peng Li , Mark Leo Michaels , Mei-Mei Tsai
IPC: C07K14/435 , C07K16/18 , C07K14/51 , A61K47/48
CPC classification number: C07K14/435 , A61K47/60 , C07K14/51 , C07K16/18 , C07K2319/31
Abstract: The present application is directed to avimers and peptides and various combinations thereof in addition to methods of making and using them.
-
公开(公告)号：US20170183391A9
公开(公告)日：2017-06-29
申请号：US15004375
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Jeonghoon Sun , Lei-Ting Tony Tam , Mark Leo Michaels , Thomas Charles Boone , Rohini Deshpande , Yue-Sheng Li , Huiquan Han
IPC: C07K14/71
CPC classification number: C07K14/71 , A61K38/00 , C07K14/495
Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
-
14.发明授权公开(公告)号：US09493530B2
公开(公告)日：2016-11-15
申请号：US14167662
申请日：2014-01-29
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/50 , A61K38/00 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions. In some embodiments, the FGF21 mutant polypeptide comprises a substitution at position 98, 171 and/or 180.
Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。 在一些实施方案中，FGF21突变体多肽包含位置98,171和/或180处的取代。
-
公开(公告)号：US11840558B2
公开(公告)日：2023-12-12
申请号：US17357444
申请日：2021-06-24
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
CPC classification number: C07K14/05 , A61K38/1825 , A61K38/00 , A61K2039/505 , C07K16/18 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
Patent Agency Ranking
公开(公告)号：US11685770B2
公开(公告)日：2023-06-27
申请号：US16388561
申请日：2019-04-18
Applicant: AMGEN INC.
Inventor： Jeonghoon Sun , Lei-Ting Tony Tam , Mark Leo Michaels , Thomas Charles Boone , Rohini Deshpande , Yue-Sheng Li , Huiquan Han
IPC: C07K14/495 , C07K14/71 , A61K38/00
CPC classification number: C07K14/71 , C07K14/495 , A61K38/00
Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
-
公开(公告)号：US20210317176A1
公开(公告)日：2021-10-14
申请号：US17357444
申请日：2021-06-24
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
-
公开(公告)号：US20160137718A1
公开(公告)日：2016-05-19
申请号：US15004375
申请日：2016-01-22
Applicant: Amgen Inc.
Inventor： Jeonghoon Sun , Lei-Ting Tony Tam , Mark Leo Michaels , Thomas Charles Boone , Rohini Deshpande , Yue-Sheng Li , Huiquan Han
IPC: C07K14/71
CPC classification number: C07K14/71 , A61K38/00 , C07K14/495
Abstract: The present invention provides stabilized activin IIB receptor polypeptides and proteins capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the stabilized polypeptides and proteins. Compositions and methods for treating muscle-wasting diseases and metabolic disorders are also provided.
Abstract translation: 本发明提供稳定的活化素IIB受体多肽和能够结合并抑制活化素A，肌生成抑制素或GDF-11的活性的蛋白质。 本发明还提供能够产生稳定的多肽和蛋白质的多核苷酸，载体和宿主细胞。 还提供了治疗肌肉消瘦疾病和代谢紊乱的组合物和方法。
-
19.发明申请VARIANTS OF TISSUE INHIBITOR OF METALLOPROTEINASE TYPE THREE (TIMP-3), COMPOSITIONS AND METHODS 审中-公开金属蛋白酶三类（TIMP-3）组织抑制剂的变体，组成和方法公开(公告)号：US20160031969A1
公开(公告)日：2016-02-04
申请号：US14775482
申请日：2014-03-13
Applicant: AMGEN INC.
Inventor： Jeonghoon Sun , Jason Charles O'Neill , Randal R. Ketchem , Randy Ira Hecht , Edward J. Belouski , Mark Leo Michaels
IPC: C07K14/81
CPC classification number: C07K14/8146 , A61K38/00 , C12N9/6489
Abstract: There are disclosed TIMP-3 muteins, variants and derivatives, nucleic acids encoding them, and methods of making and using them.
Abstract translation: 公开了TIMP-3突变蛋白，变体和衍生物，编码它们的核酸，以及制备和使用它们的方法。
-
公开(公告)号：US20140323396A1
公开(公告)日：2014-10-30
申请号：US14167662
申请日：2014-01-29
Applicant: AMGEN INC.
Inventor： Edward John Belouski , Murielle Marie Ellison , Agnes Eva Hamburger , Randy Ira Hecht , Yue-Sheng Li , Mark Leo Michaels , Jeonghoon Sun , Jing Xu
IPC: C07K14/50
CPC classification number: C07K14/50 , A61K38/00 , C07K2319/30
Abstract: The invention provides nucleic acid molecules encoding FGF21 mutant polypeptides, FGF21 mutant polypeptides, pharmaceutical compositions comprising FGF21 mutant polypeptides, and methods for treating metabolic disorders using such nucleic acids, polypeptides, or pharmaceutical compositions.
Abstract translation: 本发明提供编码FGF21突变体多肽，FGF21突变体多肽，包含FGF21突变体多肽的药物组合物的核酸分子，以及使用此类核酸，多肽或药物组合物治疗代谢紊乱的方法。
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.023 seconds)
